BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2017

Mar 1, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2017-02-27

Reporting Person: Babu Yarlagadda S (Senior VP - Drug Discovery)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-02-27	Emp. Stock Option (Right to Buy)	$5.51	A	175000	Acquired	2027-02-27	Common Stock (175000)	Direct

Footnotes

F1: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.